Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Hepatology. 2019 Mar 14;69(6):2338–2348. doi: 10.1002/hep.30417

Table 3.

Treatment emergent adverse events by system (n=42) reported by 14 participants

System # of AEs (%)

 Dermatologic 10 (24)
 Urological 6 (14)
 Gastrointestinal 4 (10)
 Constitutional symptoms 4 (10)
 Ear/nose/throat 4 (10)
 Endocrine 3 (7)
 Neurological 3 (7)
 Infection 2 (5)
 Musculoskeletal 2 (5)
 Hematological 2 (5)
 Ophthalmic 1 (2)
 Severe respiratory 1 (2)